Dialog Online Courses Go to Training Home

Key Drug Pipeline Databases on Dialog
Lesson 3:
Pharmaprojects
(File 128/928)

Objectives
About Pharmaprojects
Why Pharmaprojects?
The Record
Exercises
Summary
Glossary
Print Tips
About the Icons


Links to Other Lessons:
  Lesson 1: Drug Pipeline Directory Basics
  Lesson 2: IMS R&D Focus (File 445/955)
  Lesson 3: Pharmaprojects (File 128/928)
  Lesson 4: Adis R&D Insight (File 107/907)
  Lesson 5: Prous Databases (Files 452,453,458,459)
  Lesson 6: Course Wrap-up
  TOC

Technical Help
with Online Courses


Need Help?
E-mail the



     

Lesson 3: Pharmaprojects (File 128/928)

The Record (cont.)

Sharon,

I know you didn't ask for this, but I thought you might want some additional marketing data on vatalanib .

I am sending you the rating information from Pharmaprojects in case it is of use to you. It’s early, but it appears that this drug has a high potential for sales.

Ric

One last field on marketing in Pharmaprojects that Sharon might want to see is the Ratings system. This field includes:

    Novelty ratings
    Market size
    Development speed
    A Total rating

This combination of ratings provides users of the file with an opportunity to see which drugs in research and development are potentially the most interesting and important.

The Update field allows for further refinements, especially if we are doing a current awareness search, where we want to keep up to date on a regular basis with the status of this drug. This field provides the latest status worldwide, as well as a history of the drug's status in all countries.
click the learn more icon to get more information

RATING:     Novelty: 6  (Leading Compound)            click the learn more icon to get more information
            Development Speed: 4  (Faster than Average)
            Market Size: 3  (US$ 2001-5000 million)
            Total Rating: 13  (Total Rating)


MAJOR EVENTS


       Event Date  A/E    Event--Details
       20060119    Est    New Indication--Macular degeneration
       20050124    Est    New Therapeutic Activity--Ophthalmological
       20031119    Est    Pharmacology Identified--VEGFR-1 and -3 
                          kinase inhibitors KI-GFEN1- and KI-GFEN3-
       20030123    Est    Change in Status--Phase III Clinical Trial
       20021121    Est    New Indication--Cancer, renal and cancer, brain
       20010621    Est    New Indication--Cancer, colorectal
       20010601    Act    Names Granted--ZK-222584
       20010515    Est    Change in Status--Phase I/II Clinical Trial
       20000803    Act    New Chemical Structure--New
       20000705    Act    New Product in Pharmaprojects

The Latest update appears higher in the record, following New Entity.

Latest Upd:    Updated On  By  Latest Change
               20070119    JB  Filing plans updated

This part of the record gives a history of the development of valatanib.

Go to the next page.

3-6


Terms of Use|Privacy Statement